Hence, we demonstrated that NFL, a promising biomarker of a variety of neurological disorders [57], can be measured across different preclinical αSyn-seeding models of variable complexity to improve our understanding of αSyn-driven neurodegeneration, as well as pharmacological interventions. Here, NEFL is linked to nervous system disorder.